Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
format_facet:"Aufsätze"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=5
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=5
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=5
PubPharm (1.434)
41
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma : A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - CARTITUDE-6
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
42
A Clinical Study to Compare Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Bone Marrow Cancer and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
43
Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide / bortezomib / dexamethasone and in lenalidomide maintenance treatment : A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma - GMMG-HD7
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
44
Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) : A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsedand/or Refractory Multiple Myeloma (RRMM)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
45
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma : Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
46
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis : A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
47
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not Responsive After Treatment or Who Had Myeloma Which Has Returned After a Period of Treatment : A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
48
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma : A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients - GMMG-CONCEPT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
49
Capability of Tofacitinib or Etanercept to accelerate clinical relevant dose reduction of non-steroidal anti-inflammatory drugs and treat-to-target guided minimization of intake of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy : Capability of Tofacitinib or Etanercept to accelerate clinical relevant tapering of non-steroidal anti-inflammatory drugs and treat-to-target guided de-escalation of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy - AcceleRAte
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
50
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma : A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[144]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Medienart: Aufsätze
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Medienart
Aufsätze
1.434
E-Artikel
1.434
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
1.434
610
Recruitment Status: Authorised-recruitment may ...
1.434
Study Type: Interventional
718
Phase: Phase 3
276
Phase: Phase 2
124
Medical Condition: Multiple Myeloma MedDRA vers...
116
Phase: Phase 4
50
Phase: Phase 1
40
Medical Condition: Multiple myeloma MedDRA vers...
40
Medical Condition: Relapsed/Refractory Multiple...
36
Medical Condition: Relapsed or Refractory Multi...
24
Medical Condition: Plasma cell myeloma MedDRA v...
24
Medical Condition: Relapsed or Refractory Multi...
24
Medical Condition: Smoldering Multiple Myeloma ...
22
Medical Condition: ASTHMA UNCONTROLLED ON MEDIU...
22
Medical Condition: Moderate and Severe Atopic D...
20
Medical Condition: Patients with Relapsed Refra...
16
Medical Condition: MULTIPLE MYELOMA MedDRA vers...
16
Medical Condition: Relapsed and lenalidomide-re...
12
Medical Condition: Atopic Dermatitis MedDRA ver...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
862
2020-
572
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.382
Englisch
38
Unbestimmt
8
Französisch
4
Dänisch
2
Spanisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...